Please note that due to a high volume of submissions, the ANZCTR is currently experiencing a delay in processing of submissions.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00164073




Registration number
NCT00164073
Ethics application status
Date submitted
13/09/2005
Date registered
14/09/2005
Date last updated
1/08/2007

Titles & IDs
Public title
Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection
Scientific title
Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection
Secondary ID [1] 0 0
122/03
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatitis C 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Treatment: Surgery - Liver biopsy

Treatment: Surgery: Liver biopsy


Intervention code [1] 0 0
Treatment: Surgery
Comparator / control treatment
Control group

Outcomes

Eligibility
Key inclusion criteria
- HCV mono-infection, no coagulopathy and having a liver biopsy for consideration of
treatment
Minimum age
18 Years
Maximum age
70 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Infection with HIV or HBV, excess ethanol (EtOH) consumption and other diseases of the
liver

Study design
Purpose
Duration
Longitudinal
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Unknown status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
3181 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
Bayside Health
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
University of Adelaide
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to examine gene expression profiles by DNA microarray in
patients who are responders and non-responders to interferon and ribavirin treatment for
hepatitis C virus (HCV). Genes involved in inflammation and fibrosis and mediators of the
Th-1 lymphocyte response will be looked for. It is hoped that genetic targets for future more
effective and less toxic treatments will be identified.
Trial website
https://clinicaltrials.gov/show/NCT00164073
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Mark D Berzsenyi, MBBS
Address 0 0
The Alfred
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Mark D Berzsenyi, MBBS
Address 0 0
Country 0 0
Phone 0 0
0417 574 015
Fax 0 0
Email 0 0
m.berzsenyi@alfred.org.au
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT00164073